By Fineline Cube The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration has published the 106th batch of chemical generic reference preparations. The latest release includes 27 newly added specifications and updates to 7 previously published specifications, while 4 specifications failed to meet regulatory standards during the review process.
Regulatory Update Summary
| Item | Detail |
|---|---|
| Agency | CDE/NMPA (China) |
| Batch Number | 106th batch |
| New Specifications Added | 27 |
| Previously Published Updated | 7 |
| Specifications Failed Review | 4 |
| Publication Date | 22 Apr 2026 |
| Impact Scope | Chemical generic drug manufacturers seeking market authorization in China |
Key Developments
- Reference Preparations Framework: The CDE’s reference preparation system serves as the gold standard for generic drug equivalence studies in China’s pharmaceutical market
- Quality Standards Enhancement: Updated specifications reflect evolving quality, safety, and efficacy requirements aligned with international regulatory practices
- Market Access Implications: Generic manufacturers must reference these approved preparations when conducting bioequivalence studies for ANDA submissions
- Regulatory Stringency: The rejection of 4 specifications demonstrates the CDE’s rigorous evaluation standards and commitment to maintaining high-quality reference standards
- Industry Guidance: Updated information for previously published specifications provides clarity on analytical methods, impurity profiles, and stability requirements
Market Impact Assessment
| Aspect | Analysis |
|---|---|
| Generic Drug Development | Direct impact on ~150–200 pending ANDA applications referencing these specifications |
| Market Competition | New reference preparations may accelerate generic entry for previously unprotected molecules |
| Manufacturing Standards | Raises the bar for quality control and analytical capabilities among domestic manufacturers |
| International Alignment | Continued harmonization with FDA/EMA reference standards facilitates global development strategies |
| Regulatory Efficiency | Clear reference standards reduce review cycles and approval timelines for compliant applications |
Strategic Context
China’s ongoing pharmaceutical regulatory reform has placed significant emphasis on establishing robust reference preparation systems to ensure generic drug quality and therapeutic equivalence. The CDE’s systematic approach to regularly updating and expanding the reference preparation catalog reflects the country’s commitment to maintaining a reliable foundation for generic drug development.
For pharmaceutical companies operating in or targeting the Chinese market, staying current with CDE reference preparation updates is critical for successful generic drug development strategies. The inclusion of new specifications opens opportunities for first-to-file generic applications, while updated guidelines may require existing development programs to be reassessed or modified.
The rejection of 4 specifications serves as a reminder that the CDE maintains strict quality thresholds, and companies should conduct thorough due diligence before selecting reference preparations for their bioequivalence studies.
Forward-Looking Statements
This brief contains statements regarding regulatory developments and market impacts. Actual outcomes may vary based on individual company development strategies, competitive dynamics, and evolving regulatory interpretations.-Fineline Info & Tech